Linda Llewelyn, the Chief People Officer at Health Catalyst , Inc. (NASDAQ:), recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On January 15, Llewelyn sold 6,442 shares of common stock at an average price of $5.7976 per share, totaling approximately $37,348. Following this transaction, Llewelyn retains ownership of 92,260 shares in the company. This sale was conducted under a pre-arranged trading plan established in March 2024, in accordance with Rule 10b5-1.The sale comes as Health Catalyst trades near its 52-week low of $5.35, with the stock down over 20% in the past week. According to InvestingPro analysis, the stock appears undervalued at current levels, with analysts projecting profitability this year despite recent market pressure. InvestingPro subscribers have access to 8 additional key insights about Health Catalyst, including detailed financial health scores and comprehensive valuation metrics.
In other recent news, Health Catalyst has been the focus of several significant developments. The company announced a definitive agreement to acquire Upfront Healthcare Services (NASDAQ:), a patient engagement platform provider, expected to close in the first quarter of 2025. This acquisition aims to enhance Health Catalyst’s existing patient engagement portfolio and streamline patient care.
Health Catalyst also disclosed its positive third-quarter financial results for 2024, with a revenue mix shifting back towards software. Analyst firms such as KeyBanc Capital Markets, Piper Sandler, and Stephens have shown optimism for the company’s performance, upgrading the stock and raising the price target. KeyBanc upgraded Health Catalyst from Sector Weight to Overweight, while Piper Sandler and Stephens increased the price target on the company’s stock.
In terms of analyst ratings, RBC Capital has cut the stock target for Health Catalyst to $7, maintaining a Sector Perform rating. This decision reflects the firm’s cautious stance as they monitor Health Catalyst’s ability to convert new client bookings into sustained revenue growth. However, the firm expressed optimism about Health Catalyst’s bookings outlook for 2025, anticipating around 40 net new clients.
These are recent developments that provide investors with insights into the financial health and growth trajectory of Health Catalyst. The company’s actions and financial results, coupled with the perspectives of various analyst firms, offer a snapshot of Health Catalyst’s current business landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
